BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

Taysha raises $157M in IPOShares of Taysha Gene Therapies Inc. (NASDAQ:TSHA) rose $4.06 (20%) to $24.06 in the CNS disorders company’s first day of trading, after it raised $157 million in an upsized IPO through the sale...
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

Axxam spinout Libra is targeting autophagy and toxic protein production pathways common to multiple neurodegenerative disorders, starting with ALS. Libra Therapeutics Inc. emerged from stealth Wednesday...
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

IPOs by preclinical biotechs since 2013 had largely been hit or miss until the past 18 months, when a trend toward positive aftermarket performance has emerged. Sixty percent of the 53 preclinical IPOs on NASDAQ...
BioCentury | Apr 23, 2020
Product Development

Viral antigen tests on deck as world awaits validation of COVID-19 serology

As companies and regulators grapple with the accuracy of serological tests that detect past exposure to the novel coronavirus, another type of immunoassay aimed at spotting presymptomatic infections is poised to go from zero to...
BioCentury | Nov 1, 2019
Politics & Policy

Survey finds Europe top alternative for Chinese life science investors amid CFIUS concerns

A survey of Chinese investors revealed broad concern about U.S. restrictions on foreign investment in the life sciences that is diverting Chinese investments to other countries, with Europe cited as the top alternative for investment....
BioCentury | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BioCentury | Nov 10, 2018
Clinical News

NKTR-214 CR data at SITC suggest advantage over SOC

Updated Phase I/II data presented Friday for NKTR-214 from Nektar Therapeutics (NASDAQ:NKTR) plus Opdivo nivolumab to treat previously untreated patients with metastatic stage IV melanoma showed an objective response rate (ORR) that included more patients...
BioCentury | Nov 6, 2018
Politics & Policy

FDA releases real-world data collection app

FDA released on Tuesday an open source code app that can be used to collect real-world data directly from patients, including from mobile devices. The MyStudies app is a digital platform that users can adapt...
BioCentury | Aug 30, 2018
Tools & Techniques

Master of autism

The discovery of a master regulator of autism risk genes has yielded the first mouse model of the form of the condition that accounts for about 90% of patients, and could spark a new way...
Items per page:
1 - 10 of 38
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

Taysha raises $157M in IPOShares of Taysha Gene Therapies Inc. (NASDAQ:TSHA) rose $4.06 (20%) to $24.06 in the CNS disorders company’s first day of trading, after it raised $157 million in an upsized IPO through the sale...
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

Axxam spinout Libra is targeting autophagy and toxic protein production pathways common to multiple neurodegenerative disorders, starting with ALS. Libra Therapeutics Inc. emerged from stealth Wednesday...
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

IPOs by preclinical biotechs since 2013 had largely been hit or miss until the past 18 months, when a trend toward positive aftermarket performance has emerged. Sixty percent of the 53 preclinical IPOs on NASDAQ...
BioCentury | Apr 23, 2020
Product Development

Viral antigen tests on deck as world awaits validation of COVID-19 serology

As companies and regulators grapple with the accuracy of serological tests that detect past exposure to the novel coronavirus, another type of immunoassay aimed at spotting presymptomatic infections is poised to go from zero to...
BioCentury | Nov 1, 2019
Politics & Policy

Survey finds Europe top alternative for Chinese life science investors amid CFIUS concerns

A survey of Chinese investors revealed broad concern about U.S. restrictions on foreign investment in the life sciences that is diverting Chinese investments to other countries, with Europe cited as the top alternative for investment....
BioCentury | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BioCentury | Nov 10, 2018
Clinical News

NKTR-214 CR data at SITC suggest advantage over SOC

Updated Phase I/II data presented Friday for NKTR-214 from Nektar Therapeutics (NASDAQ:NKTR) plus Opdivo nivolumab to treat previously untreated patients with metastatic stage IV melanoma showed an objective response rate (ORR) that included more patients...
BioCentury | Nov 6, 2018
Politics & Policy

FDA releases real-world data collection app

FDA released on Tuesday an open source code app that can be used to collect real-world data directly from patients, including from mobile devices. The MyStudies app is a digital platform that users can adapt...
BioCentury | Aug 30, 2018
Tools & Techniques

Master of autism

The discovery of a master regulator of autism risk genes has yielded the first mouse model of the form of the condition that accounts for about 90% of patients, and could spark a new way...
Items per page:
1 - 10 of 38